Type 2 Diabetes | Treatment Algorithms | Claims Data Analysis | US | 2020

Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of more-effective, safer, and/or better-tolerated therapies, such as the sodium glucose contransporter-2 (SLGT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have provided physicians with a broad array of therapeutic options. Moreover, with better understanding of type 2 diabetes and its complications, individualization of treatment is becoming more common. Numerous branded agents from both established and recently emergent classes are now jostling for position in the treatment paradigm.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed type 2 diabetes patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed type 2 diabetes patients?
  • How have Steglatro, Ozempic, Rybelsus, and Tresiba been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of type 2 diabetes patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of type 2 diabetes patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?
Login to access report

launch Related Market Assessment Reports